EMJ Oncology 8 [Supplement 3] . 2020

Patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) derive little benefit from standard therapies and have an extremely poor prognosis. Recent data has demonstrated that adding an anti-epidermal growth factor receptor (EGFR) agent to a BRAF inhibitor, with or without an MEK inhibitor, improves overall survival and response rates compared to irinotecan-based chemotherapy for these patients.